[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544005":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":51,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Sengkang General Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Obese",null,"Patients with BMI \\> 27.5 kg\u002Fm2",[13],"Other: No specific intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"Sarcopenic","Patients who are sarcopenic, defined by the Asian Working Group on Sarcopenia 2014 criteria, which is defined as\n\n1. having low handgrip strength (\\\u003C26kg for males; \\\u003C18kg for females) AND\u002FOR\n2. Low gait speed (\\\u003C0.8m\u002Fs) AND\n3. Low muscle mass (\\\u003C7.0kg\u002Fm2 for males; \\\u003C5.7kg\u002Fm2 for females)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Controls","Healthy volunteers who are not obese (BMI \\\u003C27.5kg\u002Fm2), OR who are screened and found to not be sarcopenic",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"No specific intervention","Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group).\n\nFollow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention\n\nControl subjects will have no interventions performed as well.",[19,9,15],[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Koy Min Chue","CONTACT","69305000","chue.koy.min@singhealth.com.sg",[34],{"facility":5,"status":35,"city":36,"state":10,"zip":37,"country":36,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Singapore","544886","SG",{"type":40,"coordinates":41},"Point",[42,43],103.85007,1.28967,{"lat":43,"lon":42},[46],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chue Koy Min","Clinical Assistant Professor",[52,54,56],{"name":53,"class":6},"Singapore General Hospital",{"name":55,"class":6},"Nanyang Technological University",{"name":57,"class":6},"Duke-NUS Graduate Medical School","100544005","pilot-study-of-the-human-metagenome-in-metabolic-diseases-100544005",false,"NCT06363253","Pilot Study of the Human Metagenome in Metabolic Diseases","Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study","Inclusion Criteria (obese cohort):\n\n* Obese (BMI\\>27.5kg\u002Fm2)\n\nInclusion Criteria (sarcopenic cohort):\n\n* Sarcopenic patients, defined as 1) low handgrip strength (\\\u003C26 for males; \\\u003C18kg for females), AND\u002FOR low gait speed (\\\u003C0.8m\u002Fs) AND low muscle mass (\\\u003C7.0kg\u002Fm2 for males; \\\u003C5.7kg\u002Fm2 for females)\n\nInclusion Criteria (control cohort):\n\n\\- Healthy subjects without sarcopenia, and not obese (BMI\\\u003C27.5kg\u002Fm2)\n\nExclusion Criteria:\n\n* No informed consent\n* Presence of intestinal stoma, hence inability to collect fecal samples",true,"ALL","21 Years","99 Years",{"count":70,"type":71},600,"ESTIMATED","OBSERVATIONAL","This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.\n\nRecruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.\n\nWe hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.",[75,76,77,78,79],"Obesity","Sarcopenia","Sarcopenic Obesity","Chronic Inflammation","Metabolic Syndrome",[75,76,81,82,83],"Metabolic syndrome","Metagenomics","Metabolomics","2025-05-12",{"date":86,"type":87},"2025-05-15","ACTUAL",{"date":89,"type":87},"2023-08-14",{"date":91,"type":71},"2027-12-31",{"name":5,"class":6},1]